Name: Return on Equity (ROE)

Definition: ROE shows how much profit the company earns for its shareholders based on their invested equity. It’s one of the most watched profitability ratios. A consistently high ROE signals strong management and efficient use of shareholder capital. But artificially high ROE may sometimes be boosted by excessive debt.

Interpretation:
• In '2021', PRME's return on equity was -69.0%, measuring profitability for shareholders. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2021' stood at -39.7%.
• In '2022', PRME's return on equity was -43.8%, measuring profitability for shareholders. The increase since '2021' reflects strengthening financial performance. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2022' stood at -47.7%. Industry average declined by 8.0% from previous year.
• In '2023', PRME's return on equity was -88.2%, measuring profitability for shareholders. The decline from '2022' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2023' stood at -49.0%. Industry average declined by 1.3% from previous year.
• In '2024', PRME's return on equity was -136.9%, measuring profitability for shareholders. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: Biological Products (No Diagnostic Substances) in '2024' stood at -62.5%. Industry average declined by 13.4% from previous year.
Overall, PRME's return on equity has been volatile but showed a downward trend over the past 4 years.

Formula: ROE = Net Income / Shareholders' Equity

Good Range: 10%-20% desirable for many industries.